诺和诺德4.1亿欧元卖了个临床抗体

正文

请到「今天看啥」查看全文

IPH5401非常适合目前Innate制药的肿瘤免疫产品线的战略布局。增加了其除了腺苷通路抑制剂之外针对肿瘤微环境抗体的临床产品线，公司计划2018年开始临床试验。

Through C5aR triggering, C5a induces accumulation and activation of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment. These cells are associated with a poor prognosis across numerous tumor types. They secrete pro-tumor and pro-angiogenic factors and have emerged as a major immunosuppressive mechanism, associated with resistance to checkpoint blockers. By targeting and blocking this pathway, anti-C5aR has the potential to enhance anti-tumor immunity across a range of solid and hematologic tumors.有潜能增加针对实体瘤和血液瘤的抗肿瘤活性。

请到「今天看啥」查看全文